Literature DB >> 2685375

Detection of malignant cells in voided urine from patients with bladder cancer, a novel monoclonal assay.

K Z Walker1, P J Russell, E A Kingsley, J Philips, D Raghavan.   

Abstract

A simple assay is described for detecting malignant cells in the voided urine from patients with transitional cell carcinoma of the bladder. Agarose-embedded urothelial cells from 24 biopsy-proven cancer patients and 10 controls were stained for surface immunofluorescence with four monoclonal antibodies reactive with human bladder cancer and three monoclonals reactive with blood group A. Reactivity was assessed by fluorescence microscopy. One antibody, BLCA-8 appeared to have particular diagnostic utility. Thus, 24.3 +/- 5.8 percent of outer layer and 27.0 +/- 4.6 percent of inner layer urothelial cells reacted with BLCA-8 in patient samples, compared to 2.9 +/- 1.0 and 0.8 +/- 0.5 percent of similar cells from control urines. BLCA-8 antigen expression was found to be relatively stable even after prolonged exposure to urine. In a comparison with conventional cytology, samples from 4/8 patients were considered positive by standard methods, whereas, 8/8 were BLCA-8 positive. This new technique may thus be a useful adjunct to conventional methods.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2685375     DOI: 10.1016/s0022-5347(17)39172-3

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  8 in total

1.  Growth and metastasis of human bladder cancer xenografts in the bladder of nude rats. A model for intravesical radioimmunotherapy.

Authors:  P J Russell; I Ho Shon; G R Boniface; M E Izard; J Philips; D Raghavan; K Z Walker
Journal:  Urol Res       Date:  1991

2.  Preclinical studies of monoclonal antibodies for intravesical radioimmunotherapy of human bladder cancer.

Authors:  P J Russell; K Davis; E Kingsley; J Humphreys; J Hanley; H O'Grady; N Pearce
Journal:  Cell Biophys       Date:  1994

3.  Characterisation of the anti-bladder-cancer monoclonal antibody BLCA-8: identification of its antigen as a neutral glycolipid.

Authors:  E A Kingsley; T E Carter; K D Barrow; P J Russell
Journal:  Cancer Immunol Immunother       Date:  1995-12       Impact factor: 6.968

4.  Monoclonal antibodies for intravesical radioimmunotherapy of human bladder cancer.

Authors:  P J Russell; J Plomley; I H Shon; H O'Grady; N Pearce
Journal:  Cell Biophys       Date:  1993 Jan-Jun

5.  Targeted beta therapy of prostate cancer with 177Lu-labelled Miltuximab® antibody against glypican-1 (GPC-1).

Authors:  Mei-Chun Yeh; Brian W C Tse; Nicholas L Fletcher; Zachary H Houston; Maria Lund; Marianna Volpert; Chelsea Stewart; Kamil A Sokolowski; Varinder Jeet; Kristofer J Thurecht; Douglas H Campbell; Bradley J Walsh; Colleen C Nelson; Pamela J Russell
Journal:  EJNMMI Res       Date:  2020-05-07       Impact factor: 3.138

6.  Near-Infrared Molecular Imaging of Glioblastoma by Miltuximab®-IRDye800CW as a Potential Tool for Fluorescence-Guided Surgery.

Authors:  Dmitry M Polikarpov; Douglas H Campbell; Lucinda S McRobb; Jiehua Wu; Maria E Lund; Yanling Lu; Sergey M Deyev; Andrew S Davidson; Bradley J Walsh; Andrei V Zvyagin; David A Gillatt
Journal:  Cancers (Basel)       Date:  2020-04-16       Impact factor: 6.639

7.  Functionalized Upconversion Nanoparticles for Targeted Labelling of Bladder Cancer Cells.

Authors:  Dmitry Polikarpov; Liuen Liang; Andrew Care; Anwar Sunna; Douglas Campbell; Bradley Walsh; Irina Balalaeva; Andrei Zvyagin; David Gillatt; Evgenii Guryev
Journal:  Biomolecules       Date:  2019-12-03

8.  Glypican-1 as a Biomarker for Prostate Cancer: Isolation and Characterization.

Authors:  Quach Truong; Irene O Justiniano; Aline L Nocon; Julie T Soon; Sandra Wissmueller; Douglas H Campbell; Bradley J Walsh
Journal:  J Cancer       Date:  2016-05-21       Impact factor: 4.207

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.